Literature DB >> 6151848

Interactions of benzodiazepines on psychomotor skills.

M J Mattila.   

Abstract

Interactions of centrally active drugs are difficult to analyse in man due to methodological and ethical problems. Alcoholic and methylxanthine beverages are the most common centrally active agents that might modify the effects of benzodiazepines on performance. In sufficiently large doses ethanol enhances the effects of benzodiazepines, even those that are not metabolized by mixed function oxidases sensitive to blockade by ethanol. Consequently, the combined effect of ethanol and benzodiazepines may occur at the receptor level and/or result from altered binding of benzodiazepines to plasma proteins. Newer benzodiazepines may differ from the older in their interactions. Caffeine and theophylline counteract benzodiazepine effects on performance, resulting perhaps from the blockade of adenosine receptors which could be linked with the GABA-benzodiazepine receptor system. Central stimulants of the amphetamine type also counteract benzodiazepine effects in a somewhat selective way. New stimulant antidepressants rather counteract than increase benzodiazepine effects. Central antimuscarinics in combination with benzodiazepines are detrimental for memory. Specific benzodiazepine antagonists are effective also in man but without known clinical applications.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6151848      PMCID: PMC1463358          DOI: 10.1111/j.1365-2125.1984.tb02579.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  30 in total

1.  Aminophylline antagonises diazepam sedation.

Authors:  S B Arvidsson; B Ekström-Jodal; S A Martinell; D Niemand
Journal:  Lancet       Date:  1982-12-25       Impact factor: 79.321

2.  RO 15-1788 antagonises the central effects of diazepam in man without altering diazepam bioavailability.

Authors:  A Darragh; R Lambe; M Kenny; I Brick; W Taaffe; C O'Boyle
Journal:  Br J Clin Pharmacol       Date:  1982-11       Impact factor: 4.335

3.  Actions and interactions of diazepam and alcohol on psychomotor skills in young and middle-aged subjects.

Authors:  E S Palva; M Linnoila; P Routledge; T Seppälä
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1982-05

4.  Clinical effects and metabolism of diazepam in patients with chronic liver disease.

Authors:  J B McConnell; S H Curry; M Davis; R Williams
Journal:  Clin Sci (Lond)       Date:  1982-07       Impact factor: 6.124

5.  Alcohol does not enhance diazepam absorption.

Authors:  M Divoll; D J Greenblatt
Journal:  Pharmacology       Date:  1981       Impact factor: 2.547

6.  Interaction between effects of caffeine and lorazepam in performance tests and self-ratings.

Authors:  S E File; A J Bond; R G Lister
Journal:  J Clin Psychopharmacol       Date:  1982-04       Impact factor: 3.153

7.  Effects of alcohol on buspirone and lorazepam actions.

Authors:  T Seppälä; K Aranko; M J Mattila; R C Shrotriya
Journal:  Clin Pharmacol Ther       Date:  1982-08       Impact factor: 6.875

8.  Nomifensine, clobazam and HOE 8476: effects on aspects of psychomotor performance and cognitive ability.

Authors:  A C Parrott; I Hindmarch; P D Stonier
Journal:  Eur J Clin Pharmacol       Date:  1982-10       Impact factor: 2.953

9.  Loprazolam (HR158) and flurazepam with ethanol compared on tests of psychomotor ability.

Authors:  I Hindmarch; A C Gudgeon
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

10.  Performance impairment and increased anxiety resulting from the combination of alcohol and lorazepam.

Authors:  R G Lister; S E File
Journal:  J Clin Psychopharmacol       Date:  1983-04       Impact factor: 3.153

View more
  2 in total

Review 1.  Benzodiazepines and vigilance performance: a review.

Authors:  H S Koelega
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

2.  Unintentional drowning: Role of medicinal drugs and alcohol.

Authors:  Tuulia Pajunen; Erkki Vuori; Frank F Vincenzi; Pirjo Lillsunde; Gordon Smith; Philippe Lunetta
Journal:  BMC Public Health       Date:  2017-05-19       Impact factor: 3.295

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.